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ABSTRACT
Objectives: The aim of our study was to determine the association between the appearance of infection after modified 
posterior pelvic exenteration (MPE) and the time to adjuvant chemotherapy (TTC), and to examine whether infection has 
any impact on clinical results by delaying the start of chemotherapy. 
Material and methods: Our retrospective study analyzed 77 patients who had undergone MPE followed by adjuvant 
chemotherapy. Postoperatively, either there was no residual tumor or, the residual tumor was less than 2.5 mm, in 76.7% of 
the study patients. Our study group was divided into two subgroups for comparison; the first group consisted of 41 patients 
with postoperative infections, and the second group of 36 patients had no infections. The infections of the first group were 
monitored during a 90-day postoperative period. Median TTC and overall survival rates (OS) were determined for those 
patients who developed an infection as well as for those who did not. 
Results: The expected 5-year survival rate was 0.40 (SD = 0.09) for those patients without infection and 0.17 (SD = 0.07) for 
those patients with infection. The survival curves of patients with infection and those without infection were significantly 
different statistically (p = 0.038). The median TTC differed significantly for those patients who developed infection com-
pared with those patients who did not develop infection (37 days compared with 27.5 days respectively, p = 0.024); and 
patients without infection were statistically more likely to receive chemotherapy within 25 days following surgery than in 
the subsequent 25–42-day period compared with those patients who did develop infection (p = 0.048). No statistically 
significant differences were found between the two groups in relation to results following the initiation of chemotherapy 
during the first 42 days postoperatively (p = 0.445).
Conclusions: The absence of postoperative infection was associated with better survival rates. Patients with infection 
experienced a longer time interval between surgery and the start of chemotherapy, without negative impact to their 
overall survival rates. 
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INTRODUCTION
The prognosis for women with advanced stage (III–IV) 
ovarian cancer depends mainly on the completeness of 
the cytoreductive procedure and, it is presumed, on the 
time interval that elapses between surgery and the start 
of adjuvant chemotherapy (TTC). The standard first-line 
treatment following cytoreduction, is the administration of 
a combination of paclitaxel and carboplatin [1]. According 
to the recommendation of the European Society for Medical 
Oncology (ESMO), patients who meet the eligibility criteria 
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for receiving a human monoclonal antibody may receive 
standard chemotherapy in combination with bevacizumab 
[2–5]. The optimal time to chemotherapy remains unclear 
and opinions vary according to the clinical studies available; 
and this variety is largely due to the heterogeneous nature 
of the patient group under study. However, there is evidence 
that associates a time delay in administrating chemotherapy 
with decreased survival rates [6, 7]. The study by Wright et al. 
[8] reported that a TTC of 6 weeks or less did not influence 
OS (overall survival rates). However, the review article by 
Alexander et al. [9], recommends starting chemotherapy 
within 4 weeks of surgery. 
The extent of residual tumor tissue following surgery is 
directly related to patient survival outcomes [10–12]. For this 
reason, the aim of surgery is the removal of all neoplastic 
foci during the cytoreductive procedure, and the standard 
approach is to achieve no gross residual disease (NGR) [13]. 
In a meta-analysis, Du Bois et al. [14] reported that the re-
moval of all foci results in a median overall survival period 
of more than 99 months, while leaving a residual tumor 
of less than 1 cm correlates with a median overall survival 
rate of less than 36 months. In the 1990s, Eisenkop [15] 
introduced modified posterior pelvic exenteration (MPE) 
to facilitate the removal of all visible tumor foci. When MPE 
is performed, cancer recurrence in the Pouch of Douglas is 
significantly less likely than following a more conservative 
surgical approach based on hysterectomy [16]. Nevertheless, 
such extensive cytoreductive surgery can be associated with 
increased postoperative morbidity and mortality, because 
various postoperative complications may occur, including 
infection [17–21]. Long-term, surgical procedures such as 
large bowel resection, are risk factors for different of a variety 
of types of infection that are frequently caused by microor-
ganisms originating from the patient’s own flora [22]. 
Although numerous reasons for delaying chemotherapy 
have been established [23–25], the influence of infection on 
treatment delays has not been evaluated in women with 
advanced- stage (III and IV) ovarian cancer following MPE.
Objectives
In our study, we assessed the potential relationships 
between the appearance of infection and a longer-than-in-
tended time to chemotherapy in patients who underwent 
MPE for advanced ovarian cancer. We also analyzed the OS 
of patients with infection and those without infection in 
relation to selected variables. 
MATERIAL AND METHODS
For our study we selected 77 patients who had un-
dergone MPE from the group of women with advanced 
ovarian cancer who had had primary cytoreductive surgery 
(CRS) in the Lukaszczyk Oncological Center in Bydgoszcz 
between August 2011 and November 2015. The patients 
were diagnosed at stage III C or IV, according to the Inter-
national Federation of Gynecology and Obstetrics (FIGO) 
staging system for ovarian cancer. Multiple bowel resections, 
which are part of the surgical procedure, are associated with 
a higher frequency of perioperative infections. Therefore, all 
patients received the following antimicrobial prophylaxis 
which was commenced before they underwent surgery: 
Cefamandole IV 2.0 g 8 dosis, q 6 h, Metronidazole IV 0.5 g 
6 dosis, q 8 h and Gentamicin IV 1.5 mg/kg, based on dos-
ing weight (single dose) intraoperatively (if the duration of 
surgery was > 4 h), and according to the recommendation of 
the Hospital Infection Control Committee. However, regard-
less of the perioperative antibiotic prophylaxis used, due to 
the existences of multiple risk factors, patients undergoing 
MPE often experience infections. Directly after surgery, any 
residual tumors were evaluated by the surgeon in accord-
ance with the Sugarbaker protocol [26]. Postoperatively, 
the 77 MPE patients in our study were under the care of the 
Chemotherapy Outpatient Clinic in our center. The observa-
tion time was within the range of 17 to 2133 days. Table 1 
shows the clinical demographics of the patients we ana-
lyzed. Both demographic and clinical data were collected 
retrospectively from medical records. Information about 
the extent of each patient’s surgery and chemotherapy was 
derived from medical protocols and records. This informa-
tion included: completeness of the surgery and TTC in the 
following intervals: < 25 days, > = 25 < = 42, > 42 days (we 
have taken < = 42 days as an optimal time). Other infor-
mation, such as dose reductions, longer interval between 
cycles, types of chemotherapeutic agents, dosages, the 
number of cycles administered, and schedules, as well as 
resistance to platinum, was also included. A carboplatin/pa-
clitaxel-containing chemotherapeutic regimen was used as 
a standard treatment; and where that was not used, the fol-
lowing treatments were used: cisplatin/cyclophosphamide, 
carboplatin/cyclophosphamide, cisplatin/taxol, and carbo-
platin/gemcitabine. Alternatively, sometimes a one-drug 
treatment, consisting of doxorubicin, taxol, carboplatin, 
gemcitabine, was applied. Four patients who met the eligi-
bility criteria for receiving a human monoclonal antibody 
received the standard carboplatin and paclitaxel chemo-
therapy in combination with bevacizumab. If the cancer 
progressed within 6 months of the completion of therapy 
the tumor was defined as platinum-resistant [27]. Informa-
tion about infections was derived from medical records, the 
Hospital Infection Control Committee, and the Microbiol-
ogy Department. We analyzed the perioperative infectious 
complications that occurred within the first 90 days follow-
ing surgery. Surgical site infections (SSI), deep surgical site 
infections, wound complications (superficial skin infection), 
organ/space infections, bloodstream infections (BSI), urinary 
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tract infections (UTI), and lower respiratory tract infections 
(LRTI), were registered and classified according to the cur-
rent criteria of the Centers for Disease Control and Preven-
tion (CDC). Information on all the patients who died after 
Table 1. Clinical demographics of analyzed patients
Variables All patients (N = 77)
Patients with 
infection (N = 41)
Patients without 
infection (N = 36)
P-value
Patients with 
infection vs patients 
without infection
Age (years), median, range 58 (26–78) 59 (26–78) 58 (30–77) 0.411
Pre-operative CA-125 value (U/mL), median, range 578.0 (17–21000) 570.0 (17–21000) 578.0 (32–14385) 0.971
Pre-operative albumin value (g/L), median, range 41.0 (31.9–49.2) 40.6 (32.0–49.2) 41.5 (31.9–48.8) 0.254
Pre-operative hemoglobin value (g/dL), median, range 12.1 (8.6–15.3) 12.4 (10–15,3) 11.8 (8.6–14.0) 0.075
Presence of diabetes, N, % 3 (3.9%) 2 (4.9%) 1 (2.8%) 0.635
ASA score, N, %
I
II
III
IV
Undefined
3 (3.9%)
33 (42.9%)
38 (49.4%)
2 (2.6%)
1 (1.3%)
0 (0.0%)
19 (46.3%)
21 (51.2%)
1 (2.4%)
0 (0.0%)
3 (8.3%)
14 (38.9%)
17 (47.2%)
1 (2.8%)
1 (2.8%)
1.000
BMI (kg/m2), median, range 25 (15–48) 26 (15–35) 25 (25–48) 0.650
Surgical procedures
Large omentectomy 61 (79.2%) 33 (80.5%) 28 (77.8%) 0.770
Total hysterectomy and bilateral salpingoophorectomy 55 (71.4%) 30 (73.2%) 25 (69.5%) 0.476
Rectosigmoidectomy 77 (100.0%) 41 (100.0%) 36 (100.0%) –
Partial small bowel resection 24 (31.2%) 13 (31.7%) 11 (30.6%) 0.913
Hemicolectomy, or a total colectomy 27 (35.1%) 15 (36.6%) 12 (33.3%) 0.765
Pelvicperitonectomy 77 (100.0%) 41 (100.0%) 36 (100.0%) –
Ileostomy 18 (23.4%) 10 (24.4%) 8 (22.2%) 0.823
Colostomy
Protective ostomy
14 (18.2%)
7 (9.1%)
9 (22.0%)
4 (9,8%)
5 (13.9%)
3 (8,3%)
0.360
0.828
Bowel anastomosis 53 (68.8%) 27 (65.9%) 26 (72.2%) 0.547
Splenectomy 28 (36.4%) 15 (36.6%) 13 (36.1%) 0.966
Histologic type, N, %
Serous tumors
Non-serous
51 (66.2%)
26 (33.8%)
26 (63.4%)
15 (36.6%)
25 (69.4%)
11 (30.6%)
0.577
Histological grading, N, %
2
3
Undefined
39 (50.6%)
25 (32.5%)
13 (16.9%)
21(51.2%)
12 (29.3%)
8 (19.5%)
18 (50.0%)
13 (36.1%)
5 (13.9%)
0.648
Lymph node involvement, N, %
N0
N1
Undefined
12 (15.6%)
32 (41.6%)
33 (42.9%)
5 (12.20%)
21 (51.2%)
15 (36.6%)
7 (19.4%)
11 (30.6%)
18 (50.0%)
0.150
Completeness of cytoreductive surgery, N, %
CCR0
CCR1
CCR2
CCR3
35 (45.5%)
24 (31.2%)
16 (20.8%)
2 (2.6%)
16 (39.0%)
16 (39.0%)
9 (22.0%)
0 (0.0%)
19 (52.8%)
8 (22.2%)
7 (19.4%)
2 (5.6%)
0.177
Total operative time (min.), median, range 312 (126–612) 348 (126–612) 300 (138–606) 0.183
Death within 30 days after surgery 1 (1.3%) 0 (0.0%) 1 (2.8%) –
Death within 6 months after surgery 12 (15.6%) 9 (22.0%) 3 (8.3%) 0.887
N0 — no regional lymph node metastasis; N1 — regional lymph node metastasis; CCR0 — indicates no residual tumor; CCR1 — less than 2.5 mm of residual tumor; 
CCR2 — between 2.5 mm and 2.5 cm of residual tumor ; CCR3 — more than 2.5 cm of residual tumor; ASA score — American Society of Anesthesiologists score; BMI 
— body mass index; CA-125 — cancer antigen 125
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CRS, was retrieved for analysis from the database of the 
Kujawsko-Pomorski regional office of the National Health 
System of Poland.
The patients in our study were divided into two sub-
groups: 41 patients with infections and 36 without. We 
compared patients who developed infections within 90 days 
of MPE with those who did not, across a range of variables in 
order to assess the homogeneity of the subgroups analyzed 
in the study, and to exclude the influence of other possible 
factors relating to the extent of the surgery that would af-
fect the OS outcome. For each subgroup, we analyzed the 
time to chemotherapy with respect to their OS. We also 
Table 2. Infectious complications within 90 days after modified posterior pelvic exenteration (n = 41)
Type of infection Number of patients
Surgical site infection 26
Urinary tract infection 4
Bloodstream infection 3
Multiple infections
Surgical site infection + Urinary tract infection 3
Surgical site infection + Lower respiratory tract infection 1
Surgical site infection + Bloodstream infection 1
Surgical site infection + Urinary tract infection + Bloodstream infection 1
Surgical site infection + Urinary tract infection + Bloodstream infection + Lower respiratory tract infection 1
Lower respiratory tract infection + Urinary tract infection + Surgical site infection 1
Total 41
Surgical site infection included wound, deep or organ/space infections
Table 3. Characteristics of adjuvant chemotherapy after surgery (number of patients  =  77)
Characteristics All patients (N = 77) %
Patients 
number
with infection 
(N = 41)
%
Patients 
number 
without 
infection
(N = 36)
%
P-value
patients with 
infection
vs patients 
without 
infection
TTC (median)
(time to chemotherapy), range, days 33 (13–153) – 37 (14–153) – 27.5 (13–120) – 0.024
TTC by intervals
– < 25 days
– ≥ 25 days ≤ 42 days
– > 42 days
– unknown
< 25 days vs ≥ 25 days ≤ 42 days
< 25 days vs > 42 days
≥ 25 days ≤ 42 days vs > 42 days
≤ 42 days vs > 42 days
21
31
23
2
27.3
40.3
29.9
2.6
7
19
13
2
17.1
46.3
31.7
4.9
14
12
10
0
38.9
33.3
27.8
0.0
0.048
0.120
0.724
0.445
Dose reduction, prolongation of time 
between cycles (all cytostatics)
– yes
– no
– unknown
22
52
3
28.6
67.5
3.9
4
25
2
34.1
61.0
4.9
8
27
1
22.2
75.0
2.8
0.355
Resistance to platinum
– yes
– no
– unknown
23
47
7
29.9
61.0
9.1
13
23
5
31.7
56.1
12.2
10
24
2
27.8
66.7
5.6
0.551
Carboplatin/paclitaxel 
chemotherapeutic regimen
– yes
– no
61
16
79.2
20.8
32
9
78.0
22.0
29
7
80.6
19.4
0.787
TTC — time to chemotherapy
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divided patients into groups according to the completeness 
of CRS and analyzed the relationships between long-term 
outcomes, and both the occurrence of infection and the 
extent of residual tumor tissue. 
The study proposal was approved by the Bioethics Com-
mittee of the Collegium Medicum Nicolaus Copernicus Uni-
versity in Bydgoszcz, No KB 80/2017.
Data analysis was performed using STATISTICA version 
13.0. Characteristics were compared between groups with 
the Chi-square test and the Mann-Whitney U test. The Ka-
plan-Meyer method was applied for calculating OS. The Log 
Rank test was used to compare the curves. The results were 
analyzed for the end points: death or information from the 
Kujawsko-Pomorski regional office of the National Health 
System of Poland that no death was reported. Differences 
were considered statistically significant at p < 0.05. Param-
eters were also expressed as medians and ranges.
RESULTS
We identified, for analysis, 77 patients with a median age 
of 58 (with a range of 26–78 years), who had received ad-
juvant chemotherapy following primary cytoreductive 
surgery (MPE). Forty-one patients (53.2%) from the group 
developed infections after surgery. SSI was observed among 
34 patients, of whom 25 developed wound infections, and 
9 deep or organ/space infections, including intra-abdominal 
abscesses. UTI was confirmed in 10 patients. BSI and LRTI 
manifested in 6 and 3 patients, respectively. In 8 of the 
41 patients who developed infections, we detected multiple 
infections in sites two, three, and four. The median time to 
the appearance of infections ranged from 12–20 days, de-
pending on the completeness of the CRS procedure. Table 2 
shows the infectious complications that we recorded ac-
cording to infection type.
The median time to postoperative chemotherapy was 
33 days (with a range of 13–153 days): 37 days in patients 
with infections (with a range of 14–153 days), and 27.5 days 
in patients without infection (with a range of 13–120 days) 
(p = 0.024). 67.6% of the patients received chemotherapy 
within the optimal time frame (i.e., within 6 weeks). Dose 
reduction or prolongation of the time between cycles 
was found in 28.6% of patients. The median number of 
chemotherapy cycles was 6 (with a range of 1–11). When 
we analyzed the results of patients both with and without 
infection, we found that approximately 63% of patients 
with infection received chemotherapy within 6 weeks of 
surgery compared with 72.0% of those without infection 
(p = 0.445). 34% of those women with infections received 
chemotherapy treatment with dose reductions or with 
a longer interval between cycles than the women who did 
not develop infection: 22.0% of patients received reduced 
doses or had a prolonged interval of time between cycles 
(p = 0.355). Chemotherapy with paclitaxel/carboplatin was 
administered in 78.0% of the patients who developed infec-
tion compared with 80.6% of the patients without infection 
(p = 0.787). In both groups of patients, the median number 
of cycles of chemotherapy was 6. 
Table 3 provides the summary of characteristics of the 
adjuvant chemotherapy. Table 4 gives further details about 
the completeness of CRS, the median time to infection, 
and TTC.
The timing of postoperative chemotherapy, whether 
under, or over, 42 days, did not impact the probability of 
survival (p = 0.715). There were no significant differences 
in the survival curves when TTC was divided into intervals 
(p = 0.622). The presence of residual cancer did affect OS 
rates. Patients with no residual tumor had a higher prob-
ability of survival compared with patients with a residual 
tumor (Fig. 1A, p = 0.001). Next, we analyzed the impact of 
the infection on OS rates. Patients from the group without 
infections had a higher probability of survival compared 
with patients with infections (Fig. 1B, p =  0.038). When we 
Table 4. Completeness of CRS and TTC and Infections stratified by patients with and without infections
Completeness of CRS
Number of 
patients with 
infections 
Median TTC
patients with 
infection, range
[days]
Median time to 
infection, range
[days]
Number of 
patients without 
infections
Median TTC
patients 
without 
infection, range
[days]
P-value
patients with 
infection
vs patients 
without 
infection 
(median TTC)
CCR0 16 38 (27–98) 12 (2-80) 19 29 (13–120)
CCR1 16 39 (17–153) 20 (3-90) 8 34 (14–56)
CCR2 9 26.5 (14–47) 13 (3-89) 7 23 (17–36)
CCR3
CCR0/CCR1 
CCR2/CCR3
0 – – 2 28.5 (16;41) 0.896
0.304
CRS — completeness of cytoreductive surgery; CCR0 — indicates no residual tumor; CCR1 — less than 2.5 mm of residual tumor; CCR2 — between 2.5 mm and 2.5 cm 
of residual tumor; CCR3 — more than 2.5 cm of residual tumor; TTC — time to chemotherapy
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Figure 1 Description
A Effect of residual disease on overall survival — statistically different survival curves in respect to CCR, among patients in whom CCR0 or CCR1 levels were achieved during surgery
B Effect of infection on overall survival — patients with infection have poorer survival outcomes compared with patients without infection
C Patients with infection have poorer survival outcomes compared with patients without infection
D No statistically significant differences in survival outcomes in relation to the occurrence or absence of infection
Figure 1 A. Graph for OS of patients with respect to completeness of cytoreductive surgery; B. Graph for OS of patients with respect to infection; C. Graph for OS of 
patients with CCR0/CCR1 level in respect to infection; D. Graph for OS of patients with CCR2/CCR3 level in respect to infection
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divided patients into two groups based on the complete-
ness of their surgery, namely CCR0/CCR1 and CCR2/CCR3, 
we observed differences that were statistically significant 
in the first group. The patients with infections had poor 
survival outcomes (Fig. 1C, p = 0.011); however, no such 
relation was demonstrated in the second group (Fig. 1D, 
p = 0.940). Our analysis of the time elapsed to the start 
chemotherapy does not confirm that there is any impact 
of infection on OS. Furthermore, there were no statistically 
significant differences between the survival curves of pa-
tients with and without infection in either the group with 
optimal TTC (< = 42 days) or the group with non-optimal TTC 
(> 42 days), (p = 0.657 and p = 0.337, respectively). 
The survival outcomes in patients with multiple infec-
tions compared with patients with just one infection site, 
when comparing the survival probability of patients with 
wound infection with those with organ/space infections 
(e.g., peritonitis), showed no statistically significant differ-
ences (p = 0.586 and p = 0.527, respectively). The expected 
5-year survival rate was 0.17 (SD = 0.07) for patients with 
A B
C D
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infections and 0.40 (SD = 0.09) for those patients without 
infections.
DISCUSSION
In our study we found that infection was common fol-
lowing primary cytoreductive surgery with MPE, and that 
it significantly affected the median TTC in patients with 
advanced ovarian cancer by 10 days. The patients without 
infection were statistically more likely to receive chemo-
therapy within 25 days after surgery than during the 25–42-
day period compared with those patients who developed 
infection. However, overall, we found that the timing of 
postoperative chemotherapy did not impact the probability 
of survival compared with the development of infection, 
regardless of the TTC, which did cause a decrease in the 
survival curves. 
To our knowledge, there are no studies evaluating the 
impact of perioperative infections on TTC, and associations 
between TTC for patients with and without infections, and 
the OS rate in women with advanced ovarian cancer (FIGO 
stage III and IV) following MPE. 
Aggressive cytoreductive surgery is associated with 
surgical site infections, predominantly wound infections, 
but it is also associated with other site infections, such as 
urinary tract infections and bloodstream infections/sepsis 
[20, 28–29]. It is unclear, however, whether the appearance 
of infection significantly affects TTC and, as a consequence, 
whether it has an impact on OS rates. The optimal time to 
chemotherapy after surgery in patients with ovarian cancer 
remains uncertain. It is known that extensive cytoreductive 
surgery and an overlapping infection (co-infection) can re-
sult in a longer recovery time and therefore delay the intend-
ed administration of chemotherapy. In our study, treatment 
delays were associated with postoperative infections. How-
ever, we did not find any correlation between a prolonged 
TTC and a decrease in the overall survival rate. Our find-
ing is like that reported in a study conducted by Nagel et 
al., where the authors pointed out there was no associa-
tion between OS rates and changes in scheduled chemo-
therapy; also indicating the importance of personalized 
treatment plans [30]. The meta-analysis by Usón et al. [31] 
indicated that there was no correlation between the 
TTC after surgery and a higher risk of death, when assessing 
patients’ 3-year survival rate following surgery with opti-
mal TTC between 20 and 40 days. However, some authors 
have suggested that the time elapsed before the start of 
chemotherapy is crucial, when considered in relation to 
the completeness of the cytoreductive surgery. Accord-
ing to a meta-analysis conducted by Mahner et al. [32], 
early chemotherapy is critical for those patients who have 
no gross residual disease following surgery. For example, 
a delay of 7 days in the initiation of chemotherapy cor-
related with a decreased OS rate. In contrast, the authors 
did not observe this correlation among patients who had 
residual cancer after cytoreduction. A similar dependence 
between early chemotherapy and a decreased OS rate has 
also been demonstrated by other authors. For instance, 
in the work of Tewari et al. [33] with a group of 1,718 pa-
tients who had a median TTC of 31 days, they found that 
27.0% of the patients began chemotherapy > 40 days after 
surgery. They also noted that the risk of death increased 
when the TTC among women with complete resection 
was > 25 days. Moreover, both Seagle et al. [6] and Hofstet-
ter et al. [7] found that the optimal time interval between 
surgery and chemotherapy was 21—35 days. In contrast 
to the research findings cited here (above), the work of 
Hofstetter et al. [7] showed that prolonging TTC negatively 
influenced OS in patients with residual disease. Feng et 
al. [34] found that TTC was longer among those patients 
who underwent bowel resection: 72.0% of such patients 
began chemotherapy > 15 days after surgery. However, 
their study did not confirm any association between the 
time to chemotherapy and OS rates. Moreover, when they 
divided patients into groups of those with, and without, 
residual diseases, they found no statistically significant 
differences. Nevertheless, the authors concluded that the 
TTC should be no longer than 6 weeks. Furthermore, both 
Wright et al. [8] and Aletti et al. [35] also reported that 
extended cytoreduction and postoperative complications 
were both associated with chemotherapy delay. In our 
study of an homogeneous group of patients with respect 
to bowel resection, namely patients after MPE, we found 
the median TTC to be 33 days. In patients with infection, 
compared with those without, the TTC differed by 9.5 days; 
however, the median TTC was still under 42 days. Matsuo et 
al. [28] observed that, among patients with perioperative 
infections (i.e., a positive microbiology result within 6 weeks 
of surgery), prolonged time to adjuvant chemotherapy 
(< 60 days compared with ≥ 60 days) was associated with 
decreased survival outcomes as well as with decreased 
treatment responses. Poor survival rates were seen in pa-
tients with perioperative infections other than uncompli-
cated urinary tract infections. However, the authors did 
not observe such a dependence when they compared the 
OS rates of patients with multiple infections with those of 
patients who developed infections in only one site. In our 
work, we observed similar associations with respect to cases 
of multiple infections. It is worth emphasizing that our work 
has also confirmed the impact of perioperative infections on 
the long-term survival outcomes of patients with advanced 
ovarian cancer, but only after MPE. 
As expected, the OS was also dependent on the tumor’s 
residual status. Patients in our study with smaller residual 
tumors had better survival outcomes. Our observations also 
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confirmed that the appearance of infection was associated 
with decreased survival outcomes among patients with no 
residual tumor or with a residual tumor of less than 2.5 mm 
(CCR0/CCR1). Interestingly, we did not record a correspond-
ingly similar association in the cases of residual tumors of 
CCR2/CCR3. It seems that this latter fact may be related to 
complications that were associated with stoma formation; 
however, the retrospective nature of our research did does 
not allow for us to undertake a comparative analysis of infec-
tious complications in ostomy and anastomosis. 
One limitation of our study was that we did not analyze 
the etiological agents of infections and their susceptibility 
to antibiotics. For the purpose of our study, we decided that 
analysis of the results of infections treated without also mak-
ing a thorough analysis of the etiological agents would be 
sufficient for our aims. The primary finding of our study was 
that infections are a common complication following MPE 
and have an impact on long-term survival outcomes. Con-
sequently, we found that a comprehensive treatment of 
ovarian cancer ought to include infection management, as 
such can improve treatment results.
CONCLUSIONS
The absence of postoperative infection was associated 
with a better survival rate in patients. We noted that patients 
with infections experienced a longer time interval between 
surgery and the start of their chemotherapy without nega-
tively impacting on their OS rates.
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